Compare CBRL & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CBRL | SLN |
|---|---|---|
| Founded | 1969 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 1998 | 2010 |
| Metric | CBRL | SLN |
|---|---|---|
| Price | $69.60 | $19.81 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 9 | 5 |
| Target Price | ★ $50.71 | $19.75 |
| AVG Volume (30 Days) | 643.2K | ★ 4.2M |
| Earning Date | 12-08-2026 | 11-12-2026 |
| Dividend Yield | ★ 1.47% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.40 | N/A |
| Revenue | ★ $3,030,445,000.00 | $559,000.00 |
| Revenue This Year | $1.72 | N/A |
| Revenue Next Year | $2.28 | $174.87 |
| P/E Ratio | $48.54 | ★ N/A |
| Revenue Growth | ★ 3.56 | N/A |
| 52 Week Low | $24.85 | $4.19 |
| 52 Week High | $73.67 | $19.87 |
| Indicator | CBRL | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 59.83 | 77.58 |
| Support Level | $28.43 | $19.70 |
| Resistance Level | $70.28 | $19.87 |
| Average True Range (ATR) | 2.85 | 0.06 |
| MACD | -0.53 | -0.27 |
| Stochastic Oscillator | 61.31 | 64.52 |
Cracker Barrel Old Country Store Inc operates hundreds of full-service restaurants menu that features home-style country food and a wide variety of decorative and functional items such as rocking chairs, holiday and seasonal gifts, toys, apparel, cookware and foods.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.